01 January 2001
How recombinant insulin analogs improve insulin therapy of diabetes mellitus:pathophysiology, clinical practice and recommendations.
Jan Tatoń, Zvonko Milicevic, Barbara Mozejko-Pastewka, Małgorzata Bernas, Anna Czech, Jan SkrhaMed Sci Monit 2001; 7(4): RA848-859 :: ID: 421060
Abstract
According to the latest prognoses, 300 million people are expected to sufferfrom diabetes (particularly type 2) in 2025; diabetes will become a new epidemics of the coming century.Therefore it is so important to get acquainted with the pathomechanism of diabetes-related disordersand the possibilities of effective treatment. During the last decade, numerous prospective epidemiologicalstudies have been completed, which have considerably extended our knowledge of the pathomechanism ofdisturbances and their effect on late complications of diabetes. Resistance to insulin has an importantrole in the etiology of type 2 diabetes. However, there is substantial evidence indicating that impairmentor regression of rapid insulin secretion phase at the early stage of the disease is a factor of no lesserimportance. The lack of appropriate insulin concentration after the stimulation by food ingestion (first30 min after the meal), leads to permanent, treatment-resistant hyperglycemia. The postulated attemptsto obtain a 'nearly normoglycemic' condition, as well as the results of prospective epidemiological studiesproving that achieving this aim improves the prognosis of diabetic patients, prompt the researchers tosearch for the drugs or treatment schedules, which could effectively restore the impaired insulin secretion,and its early phase in particular, in type 2 diabetes. Human insulin analogs and their pre-formulatedcommercially available mixtures seem very promising in this respect.
Keywords: Diabetes Mellitus, type 2 diabetes, type 2 diabetes, insulin mixtures, insulin analogs, humalog
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952